GI Innovation products

A novel long-acting lgE Trap-Fc fusion protein for allergic diseases; Broad therapeutic efficacy for IgE-mediated hypersensitivity reaction. Sufficient IgE control capacity for patients with high IgE levels. Low risk of anaphylactic shock and immunogenicity. High safety in GLP toxicity study.

Promotes the generation of cancer-specific effector T cell (Teff) in lymph nodes, and induces the activation and proliferation of tumor-infiltrating Teff and NK cells. Controls the immuno-suppressive function of regulatory T cells (Tregs) in tumor microenvironment (TME). Restores T cell function and anti-cancer immune responses in TME. Secures its safety in GLP toxicity study.